Synergy of plant-derived polyphenols in their salutary effects on human health
VICENTE MICOL1*, JORGE JOVEN2, ANTONIO SEGURA-CARRETERO3, CARLOS ALONSO-VILLAVERDE4, JAVIER ABEL MENÉNDEZ5
*Corresponding author & Member of AgroFOOD industry hi-tech’s Scientific Advisory Board
1. Universidad Miguel Hernández, Instituto de Biología Molecular y Celular (IBMC) Avda de la Universidad s/n, Elche, Alicante, 03202, Spain
2. Hospital Universitari de Sant Joan, IISPV. Universitat Rovira i Virgili, Centre de Recerca Biomèdica Calle Sant Llorenç 21, Reus, 43201, Spain
3. University of Granada, Department of Analytical Chemistry, Faculty of Sciences, Avda Fuentenueva, Granada, 18071, Spain
4. Hospital Son Llàtzer, Servei de Medicina Interna, Palma, Illes Balears, Spain
5. Dr Josep Trueta University Hospital, Catalan Institute of Oncology Girona (ICO-Girona), Ctra. De França s/n, Girona, 17007, Spain
Nowadays, the study of the benefi cial effects of plant food components on human health is an extremely active research fi eld, but it still has to overcome important challenges. For many years, scientists have been worried about studying the biological activity of phytochemicals, looking for single miracle molecules with outstanding in vitro properties (resveratrol, quercetin, curcumin, etc…). Nevertheless, proving their effi cacy in human trials remains to be ascertained due to inter-
individual variability, and the design of an intervention represents a major challenge (1). Particularly, the paucity of clinical data for a rational use of polyphenols, including the lack of knowledge about effective dosage, actual chemical formulation, bioavailability, distribution in tissues, the effect of genetic variations, differences in gut microfl ora, the synergistic (or antagonistic) effects observed in extracts and, consequently, most safety issues.
The pathogenesis of many human chronic diseases is of multi-factorial character. This may be the reason why single polyphenols show limited effi cacy in pathologies such as obesity, cancer or cardiovascular diseases (2, 3). ...